Results 191 to 198 of about 20,828 (198)

Dabrafenib/Dabrafenib/trametinib/Nivolumab

Reactions Weekly
openaire   +1 more source

Dabrafenib–trametinib moves to the first line in low-grade glioma

Nature Reviews Clinical Oncology, 2023
exaly  

Dabrafenib

Reactions Weekly, 2013
openaire   +1 more source

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Annals of Oncology, 2017
Evgeny Levchenko, Claus Garbe, Mario Mandala   +2 more
exaly  

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2016
David Planchard, Tae Min Kim, Julien Mazieres   +2 more
exaly  

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Lancet Oncology, The, 2012
Georgina V Long, Michael A Davies, Paolo A Ascierto   +2 more
exaly  

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology, 2022
exaly  

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

Lancet Oncology, The, 2017
Julien Mazieres, Benjamin Besse
exaly